Global Myocardial Infarction Market Report by Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, Thrombolytics), Distribution Channels (Hospitals, Hospital Pharmacies, Drug Stores, Online Drug Stores), Regions and Company Analysis 2024-2032

Global Myocardial Infarction Market Analysis

Global Myocardial Infarction Market value is foreseen to be around US$ 3.43 Billion by 2032. The CAGR for the market from 2024 to 2032 is 6.06%. Renub Research states that it amounted to US$ 2.02 Billion in 2023.

A myocardial infarction or heart attack is a risky situation that occurs because an individual does not have sufficient blood flow to some of the heart muscle. This lack of blood flow can arise due to many factors but is commonly associated with a blockage in one or more heart arteries. The affected heart muscle will start to die without blood flow. If the affected individual does not get blood flow back quickly, a myocardial infarction can cause permanent heart harm or death. A heart attack is an existence-threatening emergency. Time is crucial in treating a myocardial infarction. A delay of even a few minutes can bring about everlasting heart damage or demise.

New drugs and pipeline products for myocardial infarction (MI) in 2024 include:

Zalunfiban

A drug that treats STEMI heart attacks, which account for about 40% of heart attacks, Zalunfiban acts as an integrin alpha IIb beta3 receptor antagonist.

Selatogrel

A fast-acting, reversible, and highly selective P2Y12 inhibitor that's being developed to treat acute myocardial infarction (AMI) in patients with a history of AMI.

Cenerimod

A highly selective S1P1 receptor modulator taken as an oral once-daily tablet. Cenerimod has received Fast-Track designation from the FDA

Global Myocardial Infarction Market Growth Opportunities

•    Growing cases of Cardiovascular Disorders

Cardiovascular diseases (CVDs) impact the heart and blood arteries. One or more of these disorders may affect a heart or blood vessel component. A person may show no symptoms at all or show some. Major risk factors for heart disease and stroke include high blood pressure, high cholesterol, diabetes, smoking, secondhand smoke exposure, obesity, ineffective weight loss strategies, and an inactive lifestyle.

    In 2021- The World Heart Federation said that more than 50% of a billion people globally continue to be influenced by cardiovascular conditions, which accounted for 20.5 million demises. This is nearly a 3rd of all deaths worldwide and an increase in the envisioned 121 million CVD deaths.

So, the growing instances of cardiovascular illnesses are adding to the boom in the global myocardial infarction market.

•    Recent Technological Developments

Controlling myocardial infarction is a pivotal project and a vital juncture in the healthcare panorama in which advancements are reshaping patient care trajectory. The last decade has witnessed a profound transformation, with a burgeoning emphasis on precision medication and innovative interventions. Advanced imaging techniques, including cardiac magnetic resonance imaging (MRI) and computed tomography (CT) angiography, provide a non-invasive window into the myocardium's structure and characteristics. These innovations propel the growth of the industry. The increase in clinical trials and product approvals also drives the global myocardial infarction market.

    In June 2023 - The FDA authorized Lodoco (colchicine) to reduce the threat of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in grownup patients. Developed by Agepha Pharma, Lodoco is the first drug authorized to aim inflammation, an underlying reason for atherosclerotic cardiovascular ailment.

•    Increase in Public Campaigns and Endeavours

There has been fantastic growth in public campaigns and initiatives worldwide to increase attention to cardiovascular sicknesses. This is expected to speed up the global myocardial infarction market's growth.

    The 2023 Global Heart Hub Heart Failure Awareness Month Campaign aims to teach the public about Heart Failure. They seek to elevate attention to heart failure's signs, symptoms, and dangerous elements and the significance of early detection and effective management. Their marketing campaign for the year focuses on bringing interest to heart failure through the slogan #HighlightHeartFailure and save lives. 
    In August 2023 - the NHS established a lifesaving campaign to inspire people to call 999 while they may be having premature signs and symptoms of a heart attack, as entries for heart attack go back to pre-pandemic levels.

Challenge in the Myocardial Infarction Market

High Treatment Costs

One of the major issues existing in the myocardial infarction market is high cost of the treatment. Some of the most effective treatments that are available in saving lives include angioplasty and clot dissolving drugs which could be quite expensive to be afforded by many people in the low and middle income countries. As a global implication, the financial burden is felt by both patient population and health management systems in developed and developing world. This also keeps usage of higher end technologies such as drug eluting stents and personalized medicine out of reach, despite the fact that they show promise in delivering better results. Hence, it is important to consider these cost issues in an effort to make treatments to be available to a bigger group of people.

Slow adoption of new therapies in the myocardial infarction market

New drugs such as novel anticoagulants and genetic treatments are promising but the adoption of such applications in the treatment of patient normally takes time. This delay is attributed to the fact that drug approval processes are thoroughly stringent, there is need for many clinical trials to show functionality and safety, and finally health care providers who are protective of their patients will opt not to use drugs that have not proven their efficacy. Moreover, more awareness and acquaintance with these new options is most times required among the clinicians and the patients, which also slows adoption down. To overcome this challenge there is a need to educate stakeholders, simplify the procedures of approval of new therapies, and produce enough proofs on how these new therapies will be of benefit to society.

Europe Myocardial Infarction Market

Europe’s MI market is experiencing continuous developments in technology an treatments; France and Germany are the most progressive in the European Union in terms of advancement in healthcare. Cardiac arrest or more universally termed as heart attack still ranks high in the list of causes of mortality and morbidity in the countries in Europe and this calls for more research and development of treatment as well as preventive measures.

MI market in France is facilitated with a very effective healthcare system and the country being greatly invested in research and development. PCI constitutes one of the most representative minimally invasive practises to treat patients, and the French hospitals along with research facilities are far ahead in adopting the modern therapeutic methods like pharmacological ones. The French government’s intention to continue subsidising cardiovascular research complements the emergence of novel treatments, the optimization of existing treatments to deliver the best to the patients.

Germany also occupies a significant position in the growth of myocardial infarction market in Europe. Germany has many companies in medical technology, and many cardiovascular related equipment, for instance stents and mechanical pacemakers, which play an important role especially in the treatment of MI. German doctors stress the fact that diagnostics must be early and interventions – immediate, as they are key factors for increasing the chances of survival and decreasing the risk of the complications. Furthermore, regulatory agencies in Germany guarantee the safety and effectiveness of the new treatments enabling quick implementation of the newly developed treatments in clinical practice.

Europe might register a substantial share in the global myocardial infarction market. This is due to the significant prevalence of heart disorders in the region.

    The Lancet states in one of its articles that cardiovascular diseases are the leading reason for mortality worldwide, with an alarming 45% of all deaths in Europe attributed to them. 
To successfully address the load of cardiovascular disease in Europe, comprehensive actions must be taken at national and regional levels. 
    WHO/Europe’s Signature Initiative is a new, collaborative, incredibly targeted, pragmatic version for engaging nations with a high CVD burden to co-define and aid tailor-made tactics for a comprehensive and included technique to restore cardiovascular health.
Europe is further expected to witness a significant increase in the myocardial infarction market. This is due to product approvals by European regulatory authorities for the remedy of heart sicknesses,
    In 2022 - The European Commission (EC) granted advertising authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic persistent heart failure, Boehringer Ingelheim and Eli Lilly and Company have introduced. The landmark approval makes Jardiance® the primary and handiest accredited treatment for all adults with symptomatic continual heart failure, which includes sufferers across the full spectrum of LVEF, including both heart failure with decreased and preserved ejection fraction.

Global Myocardial Infarction Company News

The major enterprises in the global myocardial infarction industry are Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, Merck, Daiichi Sankyo, Eli Lilly and Company, Takeda, Novartis, Genentech, Amgen, Regeneron/Sanofi, Boehringer Ingelheim, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, and Mesoblast.

•    In April 2024 - Johnson & Johnson will showcase clinical and real-world evidence from its cardiovascular portfolio at the American College of Cardiology's 73rd Annual Scientific Session & Expo. The presentation will include eleven abstracts, including five oral presentations, featuring the therapeutic benefits of breakthrough medicines such as XARELTO® (rivaroxaban) and interventional technologies such as those from Abiomed® and Biosense Webster® to treat cardiovascular diseases.
•    In March 2024 - the FDA approved the weight loss drug Wegovy by Novo Nordisk to reduce the risk of serious cardiovascular complications in people with obesity and heart disease.
•    In August 2023 - Royal Philips, a global leader in health technology, showcased how it integrates AI in cardiac ultrasound and cardiac care to enhance clinical confidence and efficiency.
•    In November 2022 - Johnson & Johnson agreed to purchase Abiomed for USD 16.6 Billion. Abiomed will operate as a separate business and strengthen Johnson & Johnson MedTech's position in cardiovascular innovation. The acquisition will improve the standard of care for heart failure patients.
•    In November 2022 - A study presented at the American Heart Association found that tongxiluo, a traditional Chinese herbal ingredient, can reduce mortality risk after a heart attack by 36%. This substance could be a possible adjuvant therapy for treating STEMI, especially in low-income countries.

Drug Class – Market breakup in 9 viewpoints:

1.    Antiplatelet Agents
2.    Glycoprotein IIb/IIIa Inhibitors
3.    Antithrombotic Agents
4.    Beta-adrenergic Blockers
5.    Vasodilators
6.    Angiotensin-converting Enzyme (ACE) Inhibitors
7.    Angiotensin-receptor Blockers
8.    Analgesics
9.    Thrombolytics

Distribution Channel – Market breakup in 4 viewpoints:

1.    Hospitals
2.    Hospital Pharmacies
3.    Drug Stores
4.    Online Drug Stores

Countries – Market breakup of 25 Countries:

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

All the Key players have been covered from 3 Viewpoints:

•    Overview
•    Recent Development
•    Revenue Analysis

Company Analysis:

1.    Pfizer
2.    Sanofi-Aventis/Bristol-Myers Squibb
3.    AstraZeneca
4.    Merck
5.    Daiichi Sankyo
6.    Eli Lilly and Company
7.    Takeda
8.    Novartis
9.    Genentech
10.    Amgen
11.    Regeneron/Sanofi
12.    Boehringer Ingelheim
13.    Idorsia Pharmaceuticals
14.    Faraday Pharmaceuticals
15.    CSL Behring
16.    Immediate Therapeutics
17.    Mitsubishi Chemical Group
18.    Kancera
19.    Bayer
20.    Recardio
21.    Mesoblast

Report Details:

Customization Services available

•    Analysis of Market Size and Its Segments
•    More Company Profiles (Upto 10 without any additional cost):
•    Additional Countries (Other than mentioned Countries):
•    Region/Country Specific Reports:
•    Market Entry Strategy:
•    Region-Specific Market Dynamics:
•    Regional Market Share Analysis:
•    Trade Analysis:
•    Production Insights:
•    Others Customized Requests:

For more information contact our analysts.